네뷸라이저 시장 : 규모, 점유율, 성장, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of nebulizer Market

The global nebulizer market size was valued at USD 976.46 million in 2025 and is projected to grow from USD 1,023.80 million in 2026 to USD 1,665.04 million by 2034, exhibiting a CAGR of 6.30% during the forecast period (2026-2034). North America dominated the market with a 45.06% share in 2025, supported by strong reimbursement policies and a high prevalence of respiratory disorders.

A nebulizer is a medical drug-delivery device that converts liquid medication into a fine mist for inhalation into the lungs. It is widely used to treat chronic respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other pulmonary disorders. Increasing air pollution, smoking prevalence, and environmental triggers have significantly increased the patient population requiring inhalation therapy worldwide.

According to the World Health Organization (WHO), approximately 262.0 million people were living with asthma globally in 2019, with around 455,000 deaths reported in the same year. The growing disease burden continues to fuel demand for effective respiratory care devices.

Industry Landscape Overview

• 2025 Market Size: USD 976.46 million
• 2026 Market Size: USD 1,023.80 million
• 2034 Forecast Market Size: USD 1,665.04 million
• CAGR (2026-2034): 6.30%
• Leading Region (2025): North America - 45.06% market share

North America generated USD 440 million in 2025, maintaining its leadership due to strong healthcare infrastructure and early adoption of advanced portable nebulizers.

Market Trends

Shift Toward Vibrating Mesh Nebulizers

Technological advancements are driving a shift from traditional jet nebulizers to vibrating mesh nebulizers (VMNs). These devices offer quieter operation, consistent particle size delivery, improved portability, and enhanced patient comfort.

For instance, in June 2020, Respira Technologies launched the ultra-portable RespiRx Vibrating Mesh Nebulizer. Regulatory approvals, including FDA clearances for advanced devices such as Pulmogine, further support this transition. Growing awareness among healthcare providers regarding improved drug delivery efficiency is accelerating the adoption of mesh technology.

Market Growth Drivers

Rising Incidence of Respiratory Disorders

The increasing prevalence of asthma and COPD remains a primary growth driver. In the U.S. alone, approximately 25.0 million individuals were living with asthma, according to the Asthma and Allergy Foundation of America. Additionally, COPD affects nearly 65.0 million people globally.

Healthcare systems face substantial financial burdens due to respiratory diseases. The European Union spends nearly 6% of its healthcare budget on respiratory conditions annually, with COPD accounting for approximately 60% of that expenditure. These figures underscore the growing need for effective inhalation therapy devices.

Growing Demand for Home Healthcare

The rising cost of hospital stays is encouraging patients to shift toward homecare treatment. In the U.S., COPD inpatient hospitalization costs approximately USD 19,000 annually, while home healthcare visits cost significantly less. This economic disparity is increasing demand for portable nebulizers suitable for home use.

Healthcare providers and insurers are also promoting home-based respiratory management, further supporting market expansion.

Restraining Factors

Despite steady growth, certain limitations restrict market expansion. Nebulizers can pose infection transmission risks due to aerosol generation and unsterile components. During the COVID-19 pandemic, concerns regarding aerosol spread led some healthcare providers to prefer metered-dose inhalers (MDIs) with valved holding chambers.

Additionally, mesh nebulizers are relatively expensive, limiting adoption in developing economies. Competition from alternative inhalation devices also impacts overall market growth.

Segmentation Analysis

By Type

The market is segmented into jet, mesh, and ultrasonic nebulizers.

• The jet nebulizer segment dominated with a 50.04% share in 2026, attributed to cost-effectiveness and established clinical usage.
• The mesh nebulizer segment is expected to register the highest CAGR during the forecast period due to superior portability and advanced aerosol delivery.
• The ultrasonic segment is projected to grow steadily but remains limited by higher cost and performance constraints.

By Modality

The market is divided into portable and table-top nebulizers.

• The table-top segment accounted for 64.43% of the market share in 2026, driven by reimbursement coverage and widespread hospital usage.
• The portable segment is anticipated to grow at a higher CAGR, supported by compact design and increasing demand for homecare solutions.

By End-User

The market includes hospitals, clinics, and homecare settings.

• The hospitals segment held a 43.84% share in 2025, due to higher inpatient admissions for respiratory disorders.
• The homecare segment is gaining momentum due to cost advantages and the availability of user-friendly portable devices.
• The clinics segment shows comparatively slower growth.

Regional Insights

North America

The region generated USD 440 million in 2025, maintaining dominance due to high asthma prevalence and favorable reimbursement policies.

Europe

Europe remains the second-largest market, driven by increasing hospital admissions for respiratory diseases, including over 1.1 million respiratory-related hospitalizations in the U.K.

Asia Pacific

Asia Pacific is witnessing rapid growth due to rising pollution levels, expanding healthcare infrastructure, and product launches such as Pulmogine in China and Japan.

Latin America & Middle East & Africa

These regions are expected to grow steadily, supported by increasing awareness and improving respiratory care infrastructure.

Competitive Landscape

The market is moderately fragmented with key players including:

• OMRON Healthcare, Inc.
• Koninklijke Philips N.V.
• PARI Respiratory Equipment, Inc.
• DeVilbiss Healthcare LLC
• Briggs Healthcare
• GF Health Products, Inc.
• Trudell Medical International
• Allied Healthcare Products, Inc.
• Teleflex Medical, Inc.

Companies focus on innovation, collaborations, and digital integration. Examples include PARI's LAMIRA nebulizer authorization in Japan and Aerogen's collaboration for respiratory distress syndrome therapy.

Conclusion

The nebulizer market is expected to grow from USD 976.46 million in 2025 to USD 1,665.04 million by 2034, driven by the rising prevalence of respiratory diseases, technological advancements in mesh nebulizers, and increasing demand for home healthcare solutions. North America leads the market with a 45.06% share in 2025, while Asia Pacific presents strong growth potential. Despite challenges such as infection risks and competition from inhalers, continuous innovation and expanding healthcare access are expected to sustain steady market expansion through 2034.

Segmentation By Type

• Jet Nebulizer
• Ultrasonic Nebulizer
• Mesh Nebulizer

By Modality

• Portable
• Table-top

By End-user

• Hospitals
• Clinics
• Homecare Settings

By Geography

• North America (by Product, by Material, by Procedure, and by End-user)
  • U.S.
  • Canada
• Europe (by Product, by Material, by Procedure, and by End-user)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (by Product, by Material, by Procedure, and by End-user)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia- Pacific
• Latin America (by Product, by Material, by Procedure, and by End-user)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (by Product, by Material, by Procedure, and by End-user)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Asthma and Chronic Obstructive Pulmonary Disease (COPD), By Key Countries/Region, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Technological Advancements in Nebulizers
• 4.4. Key Industry Developments -Mergers, Partnerships, & Acquisitions
• 4.5. Impact of COVID-19 on Global Nebulizer Market

5. Global Nebulizer Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Jet Nebulizer
  • 5.1.2. Ultrasonic Nebulizer
  • 5.1.3. Mesh Nebulizer
• 5.2. Market Analysis, Insights and Forecast - By Modality
  • 5.2.1. Tabletop
  • 5.2.2. Portable
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals
  • 5.3.2. Clinics
  • 5.3.3. Homecare Settings
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Nebulizer Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Jet Nebulizer
  • 6.1.2. Ultrasonic Nebulizer
  • 6.1.3. Mesh Nebulizer
• 6.2. Market Analysis, Insights and Forecast - By Modality
  • 6.2.1. Tabletop
  • 6.2.2. Portable
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Clinics
  • 6.3.3. Homecare Settings
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Nebulizer Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Jet Nebulizer
  • 7.1.2. Ultrasonic Nebulizer
  • 7.1.3. Mesh Nebulizer
• 7.2. Market Analysis, Insights and Forecast - By Modality
  • 7.2.1. Tabletop
  • 7.2.2. Portable
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals
  • 7.3.2. Clinics
  • 7.3.3. Homecare Settings
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.4.1. U.K
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Nebulizer Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Jet Nebulizer
  • 8.1.2. Ultrasonic Nebulizer
  • 8.1.3. Mesh Nebulizer
• 8.2. Market Analysis, Insights and Forecast - By Modality
  • 8.2.1. Tabletop
  • 8.2.2. Portable
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals
  • 8.3.2. Clinics
  • 8.3.3. Homecare Settings
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Nebulizer Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Jet Nebulizer
  • 9.1.2. Ultrasonic Nebulizer
  • 9.1.3. Mesh Nebulizer
• 9.2. Market Analysis, Insights and Forecast - By Modality
  • 9.2.1. Tabletop
  • 9.2.2. Portable
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals
  • 9.3.2. Clinics
  • 9.3.3. Homecare Settings
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Nebulizer Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Jet Nebulizer
  • 10.1.2. Ultrasonic Nebulizer
  • 10.1.3. Mesh Nebulizer
• 10.2. Market Analysis, Insights and Forecast - By Modality
  • 10.2.1. Tabletop
  • 10.2.2. Portable
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals
  • 10.3.2. Clinics
  • 10.3.3. Homecare Settings
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. OMRON Healthcare, Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. PARI GmbH
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Teleflex Incorporated
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Koninklijke Philips N.V.
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. GF HEALTH PRODUCTS, INC.
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Aerogen
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Trudell Medical Limited
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Allied Healthcare Products, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. Drive DeVilbiss International
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)